On Demand Webinar: Advancing Clinical Sample Management with a Virtual Sample Repository
Title: Advancing Clinical Sample Management with a Virtual Sample Repository
Duration: 30 minutes
You’ll see how a virtual repository delivered via QuartzBio's translational hub provides visibility into clinical sample status:
- Sample visibility across studies, central labs, third party vendors, biorepositories, and disparate source systems
- KPI dashboards that report sample status including collection, processing, testing, consent, expiration – while highlighting collection gaps and discrepancies.
- Dynamic visualizations to quickly review expected vs actual sample status by patient, time point, and assay type
Webinar: Overcoming Clinical Sample Chaos — A Critical Step in Biomarker-Rich Trials
Title: Overcoming Clinical Sample Chaos: A Critical Step in Biomarker-Rich Trials
Duration: 45 minutes
You’ll see how a technology-enabled approach to clinical sample inventory management delivers:
- Sample KPI dashboards for clinical, translational, & data management teams
- Visibility into sample collection, processing, and consent status
- Dynamic visualizations to quickly review expected vs actual sample status by patient, time point, and assay type
4 Strategic Imperatives for Clinical and Biomarker Operations
Keeping track of clinical trial samples across multiple sites and vendors can be manual and tedious (recent post) -- we have demonstrated how virtual Sample Inventory Management can streamline the day-to-day reporting of sample collections, shipments, and discrepancies (webinar series).
Read More →
Streamlining vendor oversight: Monitoring site-level and laboratory performance across multiple oncology trials
The challenge: Maintaining clinical trial timelines dependent on vendor performance
A global biotechnology company with seven clinical-phase programs approached QuartzBio with a challenge shared by many organizations in the industry -- overall assessment of clinical trial vendors and sites was time-consuming and unreliable, given global site footprints, complex sample lifecycles, and inconsistent naming across sites and vendors.
Tasked with preparing regular executive summaries, the company’s clinical and biomarker operations teams were spending significant time deriving trial-wide key performance indicators (KPIs), lacking visibility into vendor performance – and challenged to translate current experience into future study Read More →
